Agents and Actions

, Volume 18, Issue 3–4, pp 407–412 | Cite as

Pharmacology of an extract of salai guggal ex-Boswellia serrata, a new non-steroidal anti-inflammatory agent

  • G. B. Singh
  • C. K. Atal
Immunosuppression and Inflammation

Abstract

Pharmacological evaluation of alcoholic extract of salai guggal (AESG) has been carried out in experimental animals. AESG displayed marked anti-inflammatory activity in carrageenan induced oedema in rats and mice and dextran oedema in rats. It was equally effective in adrenalectomised rats. In formaldehyde and adjuvant arthritis, AESG produced prominent anti-arthritic activity but no significant effect was observed in cotton pellet-induced granuloma test. It inhibited inflammation induced increase in serum transaminase levels and leucocyte counts but lacked any analgesic or anti-pyretic effects. The gestation period or parturition time in pregnant rats or onset time of castor oil-induced diarrhoea was unaffected by AESG and no significant effect was seen on cardiovascular, respiratory and central nervous system functions. No ulcerogenic effects were found in the rat stomach. The oral and intraperitoneal LD50 was greater than 2 g/Kg in mice and rats.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. [1]
    The Wealth of India. C.S.I.R. Publication. 1 Delhi, 208–210 (1948).Google Scholar
  2. [2]
    G.G. Bhargava, J.S. Negi andS.R.D. Ghua,Studies on the chemical composition of salai gum. Ind. Forester.104, 174–181 (1978).Google Scholar
  3. [3]
    Mrs R.S. Pardhy andS.C. Bhattacharyya.Structure of the serratol, a new diterpene cembranoid alcohol from Boswellia serrata Roxb. Ind. J. Chem.16B, 171–173 (1978).Google Scholar
  4. [4]
    Mrs R.S. Pardhy andS.C. Bhattacharyya.Tetracyclic triterpene acids from the resin of boswellia serrata Roxb. Ind. J. Chem.16B, 174–175 (1978).Google Scholar
  5. [5]
    Mrs R.S. Pardhy andS.C. Bhattacharyya.-boswellic acid, acetyl-boswellic acid and 11-keto-boswellic acid, four pentacyclic triterpene acids from the resin of boswellia serrata Roxb. Ind. J. Chem.16B, 176–178 (1978).Google Scholar
  6. [6]
    A. Kumar andV.K. Saxena.TLC and GLC studies of the essential oil from Boswellia serrata leaves. Ind. Drugs.16, 80–83 (1979).Google Scholar
  7. [7]
    M.K. Menon andA. Kar.Analgesic and Psychopharmacological effects of the gum resin of Boswellia serrata.Planta Medica 19, 333–341 (1971).PubMedGoogle Scholar
  8. [8]
    C.A. Winter, E.A. Risley andG.W. Nuss.Carrageenan induced oedema in hind paw of the rat as an assay for antiinflammatory drugs. Proc. Soc. Exp. Biol. Med.111, 544–547 (1962).PubMedGoogle Scholar
  9. [9]
    C.A. Winter,Anti-inflammatory testing methods: Comparative evaluation of indomethacin and other agents. In: International Symposium on ‘Non-steroidal antiinflammatory drugs’, 190–202 (1964).Google Scholar
  10. [10]
    P. Schultzer,Mortality of adrenalectomised young rats, with improved technique of operation after a period of treatment with cortical hormone. J. Physiol. (Lond.)84, 70–82 (1935).Google Scholar
  11. [11]
    R.C. Srimal andB.N. Dhawan.On the solubility of mice as an experimental animal for study of anti-inflammatory agents. Ind. J. Pharmac.3, 4 (1971).Google Scholar
  12. [12]
    H. Selye,Further studies concerning the participation of the adrenal cortex in the pathogenesis of arthritis. Brit. M. J2, 1129–1135 (1949).PubMedGoogle Scholar
  13. [13]
    C.A. Winter andC.C. Porter.Effect of alterations in side chain upon anti-inflammatory and liver glycogen activities of hydrocortisone esters. J. Amer. Pharm. Ass. Sci Ed.46, 515–519 (1957).Google Scholar
  14. [14]
    B.B. Newbould.Chemotherapy of arthritis induced in rats by mycobacterial adjuvant. Br. J. Pharmacol.21, 127–136 (1963).PubMedGoogle Scholar
  15. [15]
    B.B. Newbould.The pharmacology of fenclozic acid (2-(4-chlorophenyl)-thiazol-4-ylactic acid: I.C.I.54, 450;‘Myales’; a new compound with anti-inflammatory activity. Br. J. Pharmacol.35, 487–497 (1969).PubMedGoogle Scholar
  16. [16]
    A.P. Hanson.Quoted in Methods of enzymatic analysis p-842 (1959). (Ed)H.U. Bergmeyer. London. Academic Press (1963).Google Scholar
  17. [17]
    J. Thuilleir, P. Bessin, F. Geoffroy andJ. Godfroid.Chimic et pharmacologie de la clofezone. Chim. Ther.3, 53–67 (1968).Google Scholar
  18. [18]
    L.B. Witkin, C.F. Heubner, F. Galdi, E. O'Keefe, P. Spitaletta andA.J. Plummer.Pharmacology of 2-amino-indane hydrochloride (Su-8629): a potent nonnarcotic analgetic. J. Pharmacol. Exp. Ther.133, 400–408 (1961).PubMedGoogle Scholar
  19. [19]
    C. Bianchi andA. David.Analgesic properties of 4-ethoxycarbonyl-1-1-(2-hydroxy-3-phenoxypropyl)4-phenylpiperadine (B.D.H. 200) and some related compounds. J. Pharm. Pharmac.12, 449–459 (1960).Google Scholar
  20. [20]
    G. Brownles.A comparison on the antipyretic activity and toxicity of phenactin and aspirin. J. Pharm. Pharmac.10, 609 (1937).Google Scholar
  21. [21]
    J.H. Burn, D.J. Finney andL.G. Goodwin.Biological Standardization. Oxford University Press. 177–193 (1950).Google Scholar
  22. [22]
    G.B. Singh, R.C. Srimal andB.N. Dhawan.Pharmacological studies on 3-[-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6 hexahydro-1-(H)-pyrazino (1,2-a) quinoline hydrochloride (compound 69/183) part III. Arzneim.-Forsch.Drug Res.28, 1403–1406 (1978).Google Scholar
  23. [23]
    G.B. Singh, R.C. Srimal, S. Nityanand andB.N. Dhawan.Pharmacological studies on 3-[-(p-fluorobenzoyl propyl]-2,3,4,4a,5,6-hexahydro-1(H)-pyrazino (1, 2-a) quinoline compound 69/183) Part I. Arzneim.-Forsch./Drug Res.28, 1087–1091 (1978).Google Scholar
  24. [24]
    J.W. Aiken.Aspirin and indomethacin prolong parturition in rats: evidence that prostaglandins contribute to expulsion of foetus. Nature (Lond.), 201–21 50 (1972).Google Scholar
  25. [25]
    F. Awouters, C.J.E. Niemegeers, F.M. Lenaerts andP.A.J. Janssen.Delay of castor oil diarrhoea in rats: a new way to evaluate inhibitors of Prostaglandin biosynthesis. J. Pharm. Pharmac.30 41–45 (1978).Google Scholar
  26. [26]
    S.H. Ferreira andJ.R. Vane.Mode of action of anti-inflammatory agents which are prostaglandin synthetase inhibitors. InJ.R. Vane andS.H. Ferreira. (Eds). Handbook of Experimental Pharmacology 50/II. Springer-Verlag Berlin Heidelberg New York, 348–398 (1979).Google Scholar
  27. [27]
    M.Di. Rosa.Inhibition of cell migration in vivoand granuloma formation. InJ.R. Vane andS.H. Ferreira. (Eds). Handbook of Experimental Pharmacology: 50/II. Springer-Verlag, Berlin Heidelberg New York 223–254 (1979).Google Scholar
  28. [28]
    A. Robert.Prostaglandins, 6 523–532 (1974).PubMedGoogle Scholar
  29. [29]
    Z.N. Gaut, H. Baruth, L.O. Randall, C. Ashley andJ.R. Paulsrud.Prostaglandins.10, 59–66 (1975).PubMedGoogle Scholar
  30. [30]
    C.H. Cashin, W. Dawson andE.A. Kitchen.The pharmacology of benzoxaprofen (2-[4-chlorophenyl]-methyl-5-benzoxazola acetic acid), LRCL 3794, a new compound with anti-inflammatory activity apparently unrelated to inhibition of Prostaglandin synthesis. J. Pharm. Pharmac.29, 330–336 (1977).Google Scholar
  31. [31]
    J.R. Vane.Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs.Nature (New Biol.) 231, 232–235 (1971).Google Scholar
  32. [32]
    J.W. Aiken.Prostaglandins and prostaglandin synthetase inhibitors: studies on uterine motility and function. InH.J. Robinson, andJ.R. Vane (Eds). Prostaglandin Synthetase Inhibitors. Raven Press, New York, 289–301 (1974).Google Scholar
  33. [33]
    K.I. Williams andJ.R. Vane.Inhibition of uterine motility: the possible role of prostaglandins and aspirin like drugs. Pharmacol. Ther. B.1, 89–113 (1975).PubMedGoogle Scholar

Copyright information

© Birkhäuser Verlag 1986

Authors and Affiliations

  • G. B. Singh
    • 1
  • C. K. Atal
    • 1
  1. 1.Pharmacology Department Regional Research LaboratoryJammu-TawiIndia

Personalised recommendations